During the third quarter, the company sold three of its Renaissance systems, which were launched in 2011 for robotic guidance during minimally invasive and complex brain and spine surgery. The company also received revenue from systems sold internationally.
The company experienced an 11 percent decrease in its gross margin, to 70 percent, due to operating infrastructure development. At the same time, operating expenses increased by 30 percent during the third quarter.
Related Articles on Spine Devices:
New FDA Product Codes Make Billing for RSB Spine’s InterPlate System Easier
Medtronic Launches T2 Altitude Expandable Corpectomy Device
Ascendx Spine Names Maria Pilar Deblius-Kinsey as Sales and Marketing Manager in Europe
